Clinical trial
Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in…
NCT00351715 · AHS Cancer Control Alberta, Other · Terminated
Key facts
| NCT number | NCT00351715 |
|---|---|
| Title | Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients |
| Official title | Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients: a Phase II Multicenter, Open Label, Feasibility Study |
| Lead sponsor | AHS Cancer Control Alberta, Other |
| Collaborators | University of Calgary |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer, Pain |
| Intervention type | Drug |
| Interventions | Sublingual Methadone |
| Enrollment | 5 |
| Start date | Jul 1, 2008 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Jul 13, 2006 |
| Last update posted | Oct 21, 2019 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: